MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) is developing artificial intelligence-powered voice analysis technology to detect drug and alcohol impairment, moving away from invasive breath, saliva, and laboratory testing. The company's platform analyzes over 140 acoustic markers and is trained on more than 50 million data points to estimate intoxication levels from short voice samples. This technology is designed for both workplace and non-workplace settings, tapping into a global alcohol and drug testing devices market projected to grow from $2.5 billion in 2025 to $4.2 billion by 2033, driven by rising safety requirements and stricter regulatory oversight.
MindBio's initial commercial focus is the mining industry, particularly in South America, where large workforces and high-risk operating environments create demand for rapid impairment screening. Other potential applications include aviation, construction, call centers, law enforcement, and mental health settings where high-volume screening is expensive and time-consuming. The company aims to modernize a detection process that remains heavily dependent on breathalyzers, urine testing, and laboratory analysis.
According to the company, the market for workplace drug and alcohol detection is expanding as employers face increasing pressure to improve safety while reducing the cost and friction of traditional methods. MindBio's voice analytics approach offers a unique opportunity to streamline screening. The company has spent several years developing the technology, which can provide results from short speech samples without the need for physical samples or lengthy lab waits.
For more information on MindBio Therapeutics, visit the company's newsroom at https://ibn.fm/MBQIF.
